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SUMMARY
Identifying the molecular mechanisms that underlie
aging and their pharmacological manipulation are
key aims for improving lifelong human health. Here,
we identify a critical role for Ras-Erk-ETS signaling
in aging in Drosophila. We show that inhibition of
Ras is sufficient for lifespan extension downstream
of reduced insulin/IGF-1 (IIS) signaling. Moreover,
direct reduction of Ras or Erk activity leads to
increased lifespan. We identify the E-twenty six
(ETS) transcriptional repressor, Anterior open (Aop),
as central to lifespan extension caused by reduced
IIS or Ras attenuation. Importantly, we demonstrate
that adult-onset administration of the drug trameti-
nib, a highly specific inhibitor of Ras-Erk-ETS
signaling, can extend lifespan. This discovery of the
Ras-Erk-ETS pathway as a pharmacological target
for animal aging, together with the high degree of
evolutionary conservation of the pathway, suggests
that inhibition of Ras-Erk-ETS signaling may provide
an effective target for anti-aging interventions in
mammals.
INTRODUCTION
Ras proteins are members of a superfamily of small GTPases
that transmit signals from cell-surface receptor tyrosine kinases
(RTKs) to activate multiple downstream cell signaling pathways
(Schlessinger, 2000). Ras proteins thereby occupy a key position
in the signaling network controlling numerous cellular processes,
including proliferation, differentiation, apoptosis, senescence,
and metabolism (Goitre et al., 2014). Hyper-activation of Ras is
highly oncogenic, and approximately one-third of human tumors
present with ras mutation, a context in which Ras has been
extensively studied (Stephen et al., 2014).
Ras proteins are molecular switches that cycle between an
inactive GDP-bound state and an active GTP-bound state, the
balance of which is determined by the competing activities of
guanine nucleotide exchange factors (GEFs) and GTPase acti-
vating proteins (GAPs) (Goitre et al., 2014; Stephen et al.,
2014). In its active, GTP-bound conformation, Ras has high affin-
ity for numerous downstream effectors of RTK signal transduc-
tion pathways, including Raf, thereby activating the extracellular
signal-regulated kinase (Erk)/mitogen-activated protein kinase
(Mapk)-signaling cascade and the p110 catalytic subunit of the
class 1 phosphatidylinositol 3-kinase (PI3K), leading to activation
of the PI3K-Akt-signaling cascade (Goitre et al., 2014; Stephen
et al., 2014).
Deletion of RAS2, one of two Ras paralogs in the budding
yeast, has long been known to extend chronological lifespan
(Fabrizio et al., 2003). Recent experiments in mice indicate that
this pro-longevity function of Ras inhibition may be conserved.
Mice deficient in RasGrf1, which encodes a tissue-specific gua-
nine exchange factor for Ras (Ferna´ndez-Medarde and Santos,
2011), have been reported to live longer and maintain a better
level of motor coordination in old age than their wild-type litter-
mates (Borra´s et al., 2011). However, involvement of Ras in
determining metazoan lifespan awaits direct confirmation, as
RasGrf1 has affinity for several other ligands, including Rac,
Rho, microtubules, PI[4,5]P2, and fasfatidic acid (Mirisola and
Longo, 2011).
In mammals, Ras is a well-established signaling intermediary
of the insulin/IGF-1-signaling (IIS) pathway (White, 1997), which
plays an evolutionarily conserved role in themodulation of animal
lifespan (Fontana et al., 2010; Kenyon, 2011; Lo´pez-Otı´n et al.,
2013). Central to the capacity of reduced IIS to extend lifespan
is the regulation of the Forkhead boxO (Foxo) transcription factor
via the PI3K-Akt-Foxo branch (Fontana et al., 2010; Ortega-
Molina et al., 2012; Slack et al., 2011), yet there are no reported
pharmacological inhibitors that target this signaling pathway to
increase lifespan in any species. A role for Ras downstream of
IIS in the control of aging has remained largely unexplored
despite its potential to offer novel molecular targets for anti-
aging therapeutics.
In this study, we examine the role of Ras and its downstream
signaling effectors, Erk, and the E-twenty six (ETS) transcription
factors (TFs) during aging in Drosophila. We report that attenua-
tion of Ras-Erk-ETS signaling is implicated in the effects of
reduced IIS on aging and show that direct inhibition of Ras-
Erk-ETS signaling is sufficient to extend lifespan. Importantly,
we identify trametinib, a potent small-molecule inhibitor of
Ras-Erk-ETS signaling, as an anti-aging intervention. These find-
ings thereby define the inhibition of Ras-Erk-ETS signaling as an
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important pro-longevity mechanism that can be pharmacologi-
cally manipulated to extend animal lifespan.
RESULTS
Ras Functions Downstream of IIS in Lifespan Regulation
The insulin receptor substrates (IRS) couple insulin receptor
stimulation to the activation of downstream signaling pathways.
By binding to Grb2/Drk protein—which in turn acts as an adaptor
for the Ras GEF, SOS—IRS proteins recruit activated Ras to the
activated insulin receptor.
In order to analyze the contribution of Ras-Erk signaling to IIS-
dependent lifespan extension inDrosophila, wemutated the pro-
posed binding site for Grb2/Drk in the single Drosophila IRS
protein, Chico (Figure 1A). We first confirmed that this mutation
disrupts the interaction between the Drosophila Chico and
Grb2/Drk proteins upon insulin stimulation in vivo using the
bimolecular fluorescence complementation (BiFC) assay in
cultured S2 cells. Wild-type (Chico-WT) and Grb2/Drk-binding
mutant forms of Chico (Chico-Grb2/Drk) were tagged at their
C termini with the N-terminal fragment of YFP ([N]YFP), and
Drosophila Drk was tagged with the C-terminal fragment of
YFP ([C]YFP-Drk). Each of the YFP fragments is non-fluorescent,
but an interaction between the proteins of interest brings them in
close proximity, allowing YFP to reform and emit a fluorescent
signal. In the absence of insulin, co-expression of Chico-WT-
[N]YFP or Chico-Grb2/Drk-[N]YFP with [C]YFP-Drk did not result
in significant YFP fluorescence (Figure 1B). Insulin stimulation
of cells co-expressing Chico-WT-[N]YFP with [C]YFP-Drk pro-
duced strong YFP fluorescence (Figure 1B, effect of insulin,
Figure 1. Ras Inhibition Functions Downstream of IIS to Extend Lifespan
(A) Chico protein sequence with amino acid substitutions used to generate the Chico-Grb2/Drk- and Chico-PI3K-binding site mutants.
(B) BiFC in S2 cells co-expressing the indicated Chico constructs with theDrosophila Drk protein. Proportion of YFP-positive cells ± SE; n numbers are indicated
above each bar; **p < 0.005 Chi-square test to no insulin control. Scale bar, 10 mm.
(C) Egg-to-adult development time of the indicated genotypes. See also Figure S1.
(D) Freshweightof adult femalesof the indicatedgenotypes.Meanbodymass (n=10 for eachgenotype)±SEM,Anova,p<0.0001, **p<0.05 t test (compared toWT).
(E) Survival of wild-type and chico/+ heterozygous females carrying the indicated chico genomic rescue constructs. chico/+ flies were long-lived compared toWT
(p = 0.0006), which was rescued by the chico rescue construct (p = 0.58). Both the Grb2/Drk mutant and the PI3K mutant failed to rescue the longevity of chico/+
flies (compared to WT construct, p = 8.36 3 1010 and p = 1.32 3 109, respectively). See Table S1A.
(F) Expression of constitutively active Ras blocks the beneficial effects of chicomutation on survival. daGS/chico > ras[CA] flies show increased lifespan compared
to daGS > ras[CA] in the absence of RU486 (p = 3.07 3 1018), but not in the presence of RU486 (p = 0.18). See Table S1B.
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p = 0.003), but not in cells co-expressing Chico-Grb2/Drk-
[N]YFP with [C]YFP-Drk (Figure 1B, effect of insulin, p = 0.67).
Thus, mutation of the Grb2/Drk-binding site in Drosophila Chico
prevented its direct interaction with Drk in vivo.
To examine the role of the Grb2/Drk-binding site in fly physi-
ology, we generated flies carrying this mutation as a genomic
rescue construct alongside genomic rescue constructs contain-
ing the wild-type chico sequence as well as a second construct
with mutations to disrupt binding of Chico to the p60 subunit of
PI3K (Figure 1A). All constructs included the cis-regulatory
sequences to allow chico expression in its normal spatial and
temporal pattern and were inserted into the same genomic
location, producing similar levels of chico mRNA expression
(Figure S1A).We were therefore able to assess the ability of
wild-type or mutant forms of Chico to complement the pheno-
types of chico loss-of-function mutants under equivalent physi-
ological conditions.
To validate our experimental strategy, we examined the previ-
ously characterized role of the different domains of Chico in cell
proliferation and growth (Oldham et al., 2002).We confirmed that
the wild-type chico genomic rescue construct fully restored
several phenotypic defects associated with chico null mutation,
including developmental delay, reduced growth (Figures 1C and
1D), female sterility, and increased glycogen and lipid storage
(Figures S1B–S1D). The Grb2/Drk-binding site mutant also
fully rescued these phenotypes to the same extent as the wild-
type rescue construct, confirming that the presence of a func-
tional Grb2/Drk-binding site is not required for these functions
of Chico (Figures 1C, 1D, and S1B–S1D). The PI3K-binding
mutant behaved similarly to complete loss of chico function
(Figures 1C, 1D, and S1B–S1D), confirming that Chico requires
PI3K docking sites for its wild-type function in growth and meta-
bolism (Oldham et al., 2002), thereby substantiating our genetic
approach.
We then examined the ability of our genomic rescue con-
structs to rescue the lifespan extension associated with chico
mutation. To circumvent confounding effects of differences in
body size, metabolism, and fertility, we performed the lifespan
experiments in a chico heterozygous background, where these
phenotypes are not obvious (Oldham et al., 2002). chico hetero-
zygotes were long-lived compared to wild-type controls (Fig-
ure 1E, median lifespan +12%, p = 0.0006). As expected, the
wild-type chico construct was able to fully restore the lifespan
of chico/+ to that of wild-type flies (Figure 1E, p = 0.58). In
contrast, the PI3K-binding mutant failed to rescue chico lifespan
extension (Figure 1E, p = 1.32 3 109). Interestingly, the Grb2/
Drk-binding mutant also failed to rescue the chico lifespan
extension (Figure 1E, p = 8.363 1010), and both the PI3K-bind-
ing and Grb2/Drk-binding mutants showed an increase in
median lifespan of 15% compared to the wild-type control. To
compare the extent of lifespan extension between the two mu-
tants, we used Cox proportional hazards (CPH) analysis with
relevant a priori contrasts: the lifespan extension observed in
the Grb2/Drk-binding mutant was not significantly different
from that in the PI3K-binding mutant (p = 0.98, Table S1A).
Thus, inhibition of signaling from Chico to Ras was sufficient to
extend lifespan and to the same degree as inhibition of signaling
from Chico to PI3K.
Having established that the presence of a functional Grb2/Drk-
binding site in Chico is required for its wild-type function in life-
span, we tested whether ectopic activation of Ras can block
the beneficial effects of chico mutation on lifespan. We ex-
pressed a constitutively active form of Drosophila Ras (ras[CA])
under the control of the inducible, ubiquitous daGS driver in flies
either wild-type or mutant for chico. In non-induced flies, muta-
tion of chico resulted in a significant increase in lifespan (Fig-
ure 1F, 18% median extension, p = 3.07 3 1018). Ubiquitous
expression of ras[CA] in adults using RU486 gave short-lived flies
(Figure 1F, p = 3.97 3 1067), but altering the concentration of
dietary yeast improved their survival; thus, their lifespan retained
plasticity (Figure S2A). Nevertheless, mutation of chico did not
increase their lifespan (Figure 1F, p = 0.18). CPH confirmed
that the presence of the chico mutation had a significantly
different impact on the survival of flies with induced ras[CA]
compared to the non-induced controls (p = 7.10 3 1011, Table
S1B). Hence, activation of Ras is sufficient to prevent any bene-
ficial effects of chico mutation on survival.
Direct Inhibition of Ras-Erk Signaling Extends Lifespan
We next tested whether direct inhibition of Ras itself is sufficient
to extend lifespan by expressing a dominant-negative form of
human Ras (ras[DN]). Adult-onset, ubiquitous expression of
ras[DN] resulted in a modest but significant lifespan extension
(Figure 2A, median survival +8%, p = 1.26 3 107). In addition,
we examined the effects on lifespan of RNAi-mediated knock-
down of expression of theDrosophila ras85D gene (ras85D[RNAi]).
Adult-onset, ubiquitous RNAi against ras85D also resulted in a
significant increase in lifespan (Figure 2B, median survival +4%,
p = 0.002), confirming that reducing Ras activity is sufficient to
extend lifespan.
The canonical output of Ras activation is the Erk/Mapk
pathway (Stephen et al., 2014). To determine whether a reduc-
tion in Erk activity is sufficient to extend lifespan, we used
RNAi to knock down expression of the Drosophila ortholog of
Erk, rolled (rl[RNAi]). Adult-onset, ubiquitous RNAi knockdown
of rl significantly increased lifespan (Figure 2C, median sur-
vival +6%, p = 1.463 107). Taken together, these data demon-
strate that direct inhibition of Ras-Erk signaling can extend
lifespan.
The Drosophila gut and fat body, the latter functionally equiv-
alent to mammalian liver and adipose, have an evolutionarily
conserved function in aging (Fontana et al., 2010). We therefore
examinedwhether confining Ras-Erk inhibition to these organs is
sufficient to extend lifespan. Using the inducible, gut- and fat
body-specific S1106 driver (Poirier et al., 2008), we expressed
ras[DN], ras85D[RNAi], or rl[RNAi] specifically within these tissues.
In each case, induction of expression with RU486 resulted in
significant extension of lifespan (Figures 2D–2F, p = 3 3 103,
p = 4 3 104 and p = 1 3 105, median lifespan +7%, +1%,
and +5%, respectively). Knockdown of ras85D produced smaller
effects on lifespan than expression of ras[DN], possibly reflecting
redundancy between Ras85D and the two other Drosophila Ras
homologs, Ras64B and Roughened, which are also expressed in
the adult fat body (Chintapalli et al., 2007). Nevertheless, our
data clearly show that inhibition of Ras-Erk signaling in just these
two tissues is sufficient to extend lifespan.
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The ETS Transcription Factor, Aop, Mediates Ras-
Dependent Lifespan Effects
Key outputs of the Ras-Erk-signaling pathway during Drosophila
development are two ETS TFs: Pointed (Pnt), a transcriptional
activator stimulated by the Ras-Erk pathway, and Anterior
open (Aop), a transcriptional repressor inhibited by the pathway.
These two TFs regulate the same genes by binding to the same
regulatory elements but with opposing outcomes (Brunner et al.,
1994; Halfon et al., 2000; O’Neill et al., 1994). Inhibition of Ras ac-
tivity promotes the nuclear localization of Aop in Drosophila
larvae, and we found that, similarly, adult-onset expression of
ras[DN] using the S1106 driver resulted in a significant increase
in nuclear Aop in the adult fat body (Figure 3A, p = 5 3 103).
To further assess the transcriptional activity of Aop upon Ras
inhibition, we first had to identify Aop targets in the adult. An acti-
vated form of Aop (Aop[ACT]), mutated for eight Mapk phosphor-
ylation sites and hence resistant to repression by Erk, shows high
transcriptional activity in vivo (Brunner et al., 1994; O’Neill et al.,
1994; Rebay and Rubin, 1995). Microarray analysis of gene
expression in adult fat bodies identified two neighboring genes,
la costa (lcs) and CG1678, as strongly repressed after induction
of aop[ACT] (Alic et al., 2014). Quantitative RT-PCR on RNA iso-
lated from abdominal fat bodies confirmed this repression (Fig-
ure 3B, p < 104). Consistent with lcs and CG1678 being targets
of Aop in the adult fat body, expression of an active form of pnt
(pnt[P1]) increased their transcript levels (Figure 3B, p = 0.02)
while expression of ras[DN] decreased their expression upon
RU486 induction (Figure 3B, effect of RU486, p = 0.02). Together
with the increase in nuclear localization of Aop, this strongly in-
dicates that Ras inhibition activates Aop in the adult fat body.
Figure 2. Direct Inhibition of Ras-Erk Signaling Extends Lifespan
(A) Ubiquitous adult-onset expression of ras[DN] increases lifespan (p = 1.26 3 107). See Table S2A.
(B) Ubiquitous adult onset of ras85D knockdown by RNAi increases lifespan (p = 2 3 103). See Table S2B.
(C) Ubiquitous adult-onset knockdown of rl expression by RNAi increases lifespan (p = 1.46 3 107). See Table S2C.
(D) Adult gut/fat body expression of ras[DN] extends lifespan (p = 3 3 103). See Table S2D.
(E) Adult gut/fat body knockdown of ras85D expression by RNAi extends lifespan (p = 4 3 104). See Table S2E.
(F) Adult gut/fat body knockdown of rl expression by RNAi extends lifespan (p = 105). See Table S2F.
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We have recently shown that expression of aop[ACT] in the gut
and fat body of adult Drosophila can extend lifespan (Alic et al.,
2014). We therefore examined whether Ras and Aop act in the
same pathway to influence adult lifespan. We previously showed
that targeted knockdown of aop expression specifically in the
Figure 3. Aop Functions Downstream of
Ras in the Adult Fly to Control Lifespan
(A) Nuclear localization of Aop protein (red) in-
creases in intensity in dissected adult abdominal
fat bodies of S1106 > ras
[DN] females fed RU486.
(n = 5, p = 53 103, t test). Nuclei are stained with
DAPI (white). Scale bar, 25 mm. Intensity quantifi-
cations are shown as box plots.
(B) Box plots of log-transformed levels of lacosta
(lcs) and CG1678 mRNAs relative to actin in
females of the indicated genotypes. S1106 >
aop[ACT]: mixed effects linear model (MELM)
(n = 3–4): significant effect of RU486 (p < 104),
transcript (p = 2 3 103) and their interaction
(p = 4 3 103), with significant differences be-
tween – and + RU486 for each transcript (p <
0.05, post hoc t test); S1106>pnt
[P1]: significant
effect of RU486 only (p = 0.02, n = 4, MELM);
S1106>ras
[DN] significant effect of RU486 only
(p = 0.02, n = 4, MELM).
(C) S1106 > ras
[DN] show increased lifespan in
the presence of RU486 (p = 2 3 106), but
S1106 > ras
[DN] aop[RNAi] females do not (p =
0.95). See Table S3A.
(D) S1106 > aop
[ACT] females show increased
lifespan in the presence of RU486 (p = 2 3 105).
S1106 > aop
[ACT] ras[DN] females also show
increased lifespan in the presence of RU486
(p = 4x106) but are no longer lived than S1106 >
aop[ACT]. See Table S3B.
adult gut and fat body using RNAi has
no significant effect on lifespan (Alic
et al., 2014). RNAi-mediated knockdown
of aop expression was, however, suffi-
cient to completely block the lifespan
extension associated with gut and fat
body expression of ras[DN] (Figure 3C;
RU486 had a significant effect on the life-
span of S1106 > ras
[DN] flies, median life-
span +11%, p = 2 3 106, but not in
S1106 > ras
[DN]aop[RNAi] flies, p = 0.95).
CPH analysis confirmed that there was
a significant difference in the response
to RU486 in the two lines (RU486 by ge-
notype interaction, p = 3.2 3 103, Table
S3A). Hence, Aop is required for the
beneficial effects of Ras inhibition on
lifespan.
We next tested whether inhibition of
Ras can increase lifespan in addition to
activation of Aop in the adult gut and fat
body. Inducing ras[DN] expression in flies
already expressing aop[ACT] did not result
in any further increase in lifespan (Figure 3D). Indeed, CPH de-
tected a significant effect of RU486 (p < 104) but found no sig-
nificant difference in the response to RU486 between S1106 >
aop[ACT] and S1106 > aop
[ACT]ras[DN] flies (RU486 by genotype
interaction p = 0.35, Table S3B). Thus, inhibition of Ras does
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not further increase lifespan once Aop is already activated.
Together with the data presented above, this suggests that
Aop is both necessary and sufficient to mediate the effects of
Ras inhibition on lifespan.
AOP Is Required for chico-Dependent Lifespan
Extension
Our observation that impairing the ability of Chico to signal
through to Ras was sufficient to extend lifespan prompted
us to test whether Aop transcriptional activity also contributes
to IIS-dependent lifespan extension. Ubiquitous targeted
knockdown of aop expression by RNAi in otherwise wild-
type flies significantly impaired their survival (Figure 4A, p =
2.36 3 1016). Mutation of chico significantly increased life-
span in non-induced daGS > aop[RNAi] (median lifespan +5%,
p = 1.20 3 105), but not in RU486-induced flies (p = 0.95).
CPH confirmed that the presence of the chico mutation had
a significantly different impact on the lifespan of daGS > aop[R-
NAi] flies in the presence or absence of RU486 (Table S4A, p =
3.2 3 103).
The activity of Aop counteracts that of the Pnt transcriptional
activator, and hence, similarly to a reduction in Aop activity,
increased Pnt activity should also block any effects of chico on
survival. Ubiquitous expression of the constitutively active form
of Pnt, pnt[P1] in otherwise wild-type flies significantly impaired
their survival (Figure 4B, p = 1.66 3 1050). Their lifespan could
not be extended by chico mutation (p = 0.64, Figure 4B) but re-
mained responsive to dietary yeast (Figure S2B). At the same
time, chico mutation significantly increased lifespan in non-
induced flies (median lifespan +12%, p = 2.33 3 109). CPH
analysis of the survival data confirmed that the presence of the
chicomutation had a significantly different impact on the lifespan
of daGS > pnt[P1] flies in the presence or absence of RU486
(Table S4B, p = 1.4 3 106). Thus, counteracting the activity of
Aop by increasing that of Pnt specifically blocked any beneficial
effects of chico mutation on survival.
We also tested whether induction of aop[ACT] in the gut and fat
body could increase lifespan in addition to chicomutation. Each
intervention alone produced a significant increase in median life-
span of 7% (Figure 4C, aop[ACT] expression, p = 3.20 3 1013;
chico mutation, p = 8.84 3 107). However, the effects of each
intervention on lifespan extension were less than additive (Fig-
ure 4C and Table S4C). We also confirmed that dfoxo is required
for the lifespan extension of chico heterozygous mutation (Fig-
ure 4D; see Table S4D for details). Taken together, these data
show that, similarly to Foxo, Aop functions downstream of chico
and is essential for chico-dependent lifespan extension.
Pharmacological Inhibition of Ras-Erk-ETS Signaling
Extends Lifespan
The prolific role of Ras-Erk-ETS signaling in cancer has fueled
an intense search for small-molecule inhibitors targeting this
Figure 4. The Ras-Regulated Transcription Factor, Aop, Is Required
Downstream of chico to Increase Survival
(A) chico extends lifespan in daGS > aop[RNAi] females in the absence of RU486
(p = 1.2 3 105), but not in the presence of RU486 (p = 0.95). See Table S4A.
(B) chico extends lifespan in daGS > pnt [P1] females in the absence of RU486
(p = 2.343 109), but not in the presence of RU486 (p = 0.64). See Table S4B.
(C) The effects of chico/+ mutation and S1106 > aop
[ACT] are not additive for
lifespan (S1106 > aop
[ACT] versus S1106/chico > aop
[ACT] in the RU486
condition, p = 8.84 3 107; S1106 > aop
[ACT] RU486 versus RU486+ con-
ditions, p = 3.20 3 1013; S1106/chico > aop
[ACT] RU486 versus RU486+,
p = 0.29). See Table S4C.
(D) dfoxo is required for chico/+ lifespan extension. chico/+ females show
increased lifespan (p = 3.713 106), but not in the absence of dfoxo (p = 0.63).
See Table S4D.
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pathway. Trametinib, an FDA-approved drug for the treatment of
melanoma, is one such potent and highly specific inhibitor of the
Mek kinase, preventing activation of Erk by Ras (Yamaguchi
et al., 2011).
We first confirmed that trametinib inhibits Erk activation in
Drosophila S2 cells. Pre-treatment with trametinib over a wide
range of concentrations completely blocked both basal and in-
sulin-stimulated Erk activation (Figure 5A). Furthermore, cells
treated with the highest dose of 10 mM trametinib did not show
any inhibition of insulin-stimulated Akt or S6K phosphorylation
(Figure 5B). Thus, trametinib is a potent and specific inhibitor
of Ras-Erk signaling in flies.
To validate the Ras-Erk-ETS pathway as a drug target for
extension of animal lifespan, we tested the effects of trametinib
on Drosophila survival. Since loss-of-function mutants for
Drosophila ras are female sterile (Rørth, 1996), we first monitored
the effects of the drug on female egg laying in order to determine
the biologically relevant doses (Figure 5C). The drug was admin-
istered to adult flies orally by supplementation in the food
medium, and we selected the doses that produced small to
essentially complete inhibition of egg production (1.56 mM to
156 mM) for lifespan assays. Based on quantifications of daily
Drosophila food intake (Deshpande et al., 2014), we estimate
that flies housed on food containing 1.56 mM trametinib ingest
0.4 mg/kg body weight of the drug per day, which is compara-
ble to the oral dose used in mammalian studies of 1 mg/kg body
weight (Yamaguchi et al., 2011) and the treatment dose of 2 mg
per day for human cancer patients (Infante et al., 2012).
1.56 mM and 15.6 mM trametinib significantly increased fly life-
span (Figure 5D: 1.56 mM, median lifespan +8%, p = 2.65 3
104; 15.6 mM, median lifespan +12%, p = 1.92 3 1010). CPH
analysis revealed that, in this dose range, the risk of death per
Figure 5. Pharmacological Inhibition of Ras-Erk Signaling Using Trametinib Extends Lifespan
(A) Drosophila S2 cells treated with trametinib (Tram) at the indicated concentrations show inhibition of insulin-stimulated (Ins) Erk phosphorylation.
(B) S2 cells treated with a high concentration of trametinib (10 mM) show no inhibition of insulin-dependent phosphorylation of Akt or S6K.
(C) Effects of trametinib dose on female egg laying. Means ± SEM, **p < 0.05 t test (compared to 0 mM condition).
(D) Trametinib extends lifespan in wDah females.(1.56 mM, p = 2.65 3 104; 15.6 mM, p = 1.92 3 1010). See Table S5A.
(E) Later-life (day 30) post-reproductive (see also Figure S5) exposure to 15.6 mM trametinib extends lifespan (p = 5.02 3 105). See Table S5B.
(F) Trametinib increases survival of daGS > ras[CA] (p = 1.24 3 1039), but not daGS > pnt[P1] flies (p = 0.59) in the presence of RU486. See Table S5C.
(G) Age-related changes in gut ISC proliferation in animals exposed to trametinib for 15 or 65 days. Mean number of PH3+ cells per gut ± SEM. Number of guts
analyzed are indicated above each bar. GLM with Poisson distribution and overdispersion parameter: significant effect of age (p < 0.001), but not trametinib
concentration (p = 0.84) or their interaction (p = 0.79).
(H) Age-related changes in intestinal integrity in animals exposed to trametinib for 15 or 65 days. Proportion of smurfs present in the population ± SE. Total
numbers of flies examined for each condition are indicated above each bar. GLMwith binomial distribution and overdispersion parameter: significant effect of age
(p < 0.001), but not trametinib concentration (p = 0.84) or their interaction (p = 0.79).
(I) No significant differences in survival of GS5961 > aop[ACT] females in the presence or absence of RU486 (p = 0.45). See Table S5D.
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day was reduced by 4.7% per mM of trametinib (95% CI: 2.9%–
6.3%, Table S5A). Mortality analysis showed that treatment with
15.6 mM trametinib reduced demographic frailty (baseline mor-
tality) with no significant difference in the rate of change of mor-
tality with age (Figure S3). Such a change in baseline mortality
would be preferable for a pharmacological intervention for aging,
since it would delay the onset of mortality without prolonging the
duration of age-related decline. Higher trametinib concentra-
tions (156 mM) resulted in early life mortality but improved sur-
vival later in life, resulting in significant increases in maximum,
but not median, lifespan. Importantly, no significant effects of
trametinib were observed on feeding behavior at doses condu-
cive to lifespan extension (Figure S4).
For any pharmacological intervention into aging, it is important
it be beneficial evenwhen started late in life. We therefore admin-
istered the drug to female flies from 30 days post-eclosion, when
egg laying has almost ceased (Figure S5). This late administra-
tion also resulted in a significant extension of lifespan (Figure 5E
and Table S5B, median lifespan + 4%, p = 5.023 105). Contin-
uous exposure to the drug resulted in bigger effects on lifespan
than when drug administration was restricted to later life,
possibly reflecting cumulative effects of earlier drug exposure.
To confirm that trametinib extends lifespan by inhibition of
Ras-Erk-ETS signaling, we examined the effects of trametinib
on the survival of flies expressing constitutively active Ras or
constitutively active Pnt. In the presence of RU486, trametinib
treatment at 15.6 mM doubled the lifespan of daGS > ras[CA] (Fig-
ure 5F, p = 1.243 1039), while the survival of daGS > pnt[P1]was
unaffected by drug treatment (Figure 5F, p = 0.59). CPH analysis
confirmed that trametinib had a significantly different impact on
the lifespan of daGS > ras[CA] flies compared to daGS > pnt[P1]
flies in the presence RU486 (Table S5C, p < 2 3 1016). In the
absence of transgene expression, 15.6 mM trametinib treatment
significantly increased the lifespan of both genotypes (Figure S6).
Hence, trametinib acts specifically between Ras and Pnt to
extend fly lifespan. In summary, our data confirm that the Ras-
Erk-ETS pathway is a valid drug target for extension of animal
lifespan.
Trametinib Does Not Act on Lifespan via Modulation of
Stem Cell Proliferation
Inhibition of Ras-Erk signaling can have substantial effects on
cell proliferation. Adult Drosophila somatic tissues are predomi-
nantly post-mitotic, although a population of adult stem cells
resides in the midgut, and their proliferative capacity, in part
regulated by Ras-Erk signaling, is important for lifespan (Biteau
and Jasper, 2011; Biteau et al., 2010). To test whether trametinib
affects age-dependent intestinal stem cell (ISC) proliferation
rates, we determined the frequency of phospho-histone H3-pos-
itive (pH3+) cells, a marker of cell-cycle progression and a direct
measurement of ISC proliferation (Biteau et al., 2010). The num-
ber of PH3+ cells increased 5-fold from 15 to 65 days in control
flies, and continuous exposure to 1.56 mM or 15.6 mM trametinib
did not prevent this age-dependent increase in ISC proliferation
(Figure 5G). Hence, trametinib does not significantly affect stem
cell proliferation at doses that extend lifespan.
To further confirm that gut function was unaffected by trame-
tinib, we examined gut intestinal barrier function, which is a good
indicator of overall intestinal integrity and is important for survival
(Rera et al., 2012). Flies were fed a non-absorbable blue food
dye, and ‘‘smurf’’ flies, in which the gut is unable to prevent
this dye from leaking into the hemolymph, scored (Rera et al.,
2012). The proportion of smurfs in the control population
increased by 8-fold from 15 to 65 days (Figure 5H). Again, trame-
tinib did not alter this age-dependent loss of intestinal epithelial
integrity (Figure 5H). Consistent with these observations, we
found that adult-onset expression of Aop[ACT] specifically within
the ISCs is not sufficient to extend lifespan (Figure 5I and Table
S5D, p = 0.45). Hence, the effects of pharmacological or genetic
manipulation of Ras-Erk-ETS signaling cannot be explained by
the modulation of ISC proliferation and maintenance of gut
function.
DISCUSSION
Ras-Erk-ETS Signaling as an Effector of the IIS
Longevity Response
The key role of IIS in determining animal lifespan has been well
appreciated formore than two decades and shows strong evolu-
tionary conservation (Fontana et al., 2010; Kenyon, 2011). Alleles
of genes encoding components of this pathway have also been
linked to longevity in humans (Bonafe` et al., 2003; Kuningas
et al., 2007; Suh et al., 2008). Multiple studies have demon-
strated the importance of the PI3K-Akt-Foxo branch of IIS, while
in this study we identify an equally important role for Ras-Erk-
ETS signaling in IIS-dependent lifespan extension.
We have shown that, downstream of chico, preventing the
activation of either Ras or PI3K is sufficient to extend lifespan.
Ras can interact directly with the catalytic subunit of PI3K, which
is required for maximal PI3K activation during growth (Orme
et al., 2006). Thus, inhibition of Ras could increase lifespan via
inactivation of PI3K. However, several lines of evidence indicate
that the Erk-ETS pathway must also, if not solely, be involved. In
this study and elsewhere, we demonstrated that direct inhibition
of the Ras-dependent kinase, Erk, or activation of the Aop tran-
scription factor, a negative effector of the Ras-Erk pathway, is
sufficient to extend lifespan. Importantly, we show that Ras-
Erk-ETS signaling is genetically linked to chico because activa-
tion of Aop is required for lifespan extension due to chico loss
of function. Furthermore, altering the ability of Chico to activate
Ras or PI3K does not result in equivalent phenotypes: we and
others (Oldham et al., 2002) showed that mutation of the Grb2/
Drk docking site in Chico is dispensable for multiple develop-
mental phenotypes associated with chico mutation, while
disruption of the Chico-PI3K interaction is not. Overall, our ob-
servations strongly suggest that lifespan extension downstream
of chico mutation involves inhibition of the Ras-Erk-ETS-
signaling pathway.
The simplest model to integrate the role of Ras-Erk-ETS
signaling with the PI3K-Akt-Foxo branch in extension of lifespan
by reduced IIS is presented in Figure 6. We propose that, down-
stream of Chico, the IIS pathway bifurcates into branches delin-
eated by Erk and Akt, with inhibition of either sufficient to extend
lifespan, as is activation of either responsive TF, Aop or Foxo.
The two branches are not redundant, because mutation of chico
or the loss of its ability to activate either branch results in the
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same magnitude of lifespan extension. Furthermore, Aop and
Foxo are each individually required downstream of chico muta-
tion for lifespan extension. At the same time, the effects of the
two branches are not additive, as simultaneous activation of
Aop and Foxo does not extend lifespan more than activation of
either TF alone (Alic et al., 2014). Taken together, these data sug-
gest that the two pathways re-join for transcriptional regulation,
where Aop and Foxo co-operatively regulate genes required for
lifespan extension. Our model is corroborated by our previous
finding that, in the adult gut and fat body, some 60% of genomic
locations bound by Foxo overlap with regions of activated-Aop
binding (Alic et al., 2014).We propose that functional interactions
of Aop and Foxo at these sites may be such that each factor is
both necessary and sufficient to achieve the beneficial changes
in target gene expression upon reduced IIS.
It remains to be determined how promoter-based Foxo and
Aop interactions produce such physiologically relevant, tran-
scriptional changes. It is, however, curious that activation of
either TF alone promotes longevity when one is known as a tran-
scriptional activator (Foxo) and the other as a transcriptional
repressor (Aop). We have consistently observed a subset of
Foxo-bound genes, albeit a minority, that are transcriptionally
repressed when Foxo is activated (Alic et al., 2011, 2014).
Furthermore, the Foxo target gene myc is downregulated in
larval muscle when Foxo is active under low insulin conditions,
while deletion of foxo or its binding site within themyc promoter
results in de-repression of myc expression in adipose of fed
larvae (Teleman et al., 2008). Thus, on some promoters under
certain conditions, Drosophila Foxo appears to act as a tran-
scriptional repressor. Mammalian Foxo3a may also directly
repress some genes (Wu et al., 2013; Yang et al., 2014). It will
therefore be important to test whether the lifespan-relevant inter-
actions between Foxo and Aop occur on promoters where Foxo
acts as a repressor with Foxo possibly acting as a cofactor for
Aop or vice versa.
In mediating the effects of IIS on lifespan, the Ras-Erk-ETS-
and PI3K-Akt-Foxo-signaling pathways both appear to inhibit
Aop/Foxo. To understand why signaling might be so wired, it is
important to consider that the two pathways are also regulated
by other stimuli, such as other growth factors, stress signals,
and nutritional cues. The re-joining of the two branches at the
transcriptional level would therefore allow for their outputs to
be integrated, producing a concerted transcriptional response,
a feature that is also seen in other contexts. For example, stabil-
ity of the Myc transcription factor is differentially regulated in
response to Erk and PI3K signals, allowing it to integrate signals
from the two kinases (Lee et al., 2008). Transcriptional integra-
tion in response to RTK signaling also confers specificity during
cell differentiation, with combinatorial effects of multiple tran-
scriptional modulators inducing tissue-specific responses to
inductive Ras signals (Halfon et al., 2000). Similar integrated
responses of lifespan could be orchestrated by transcriptional
coordination of Aop and Foxo.
A Role for Ras-Erk-ETS Signaling in Mammalian Aging
We find that direct inhibition of Ras in Drosophila can extend life-
span, suggesting that the role of Ras in aging is evolutionarily
conserved. In budding yeast, deletion of RAS1 extends replica-
tive lifespan (Sun et al., 1994), and deletion of RAS2 increases
chronological lifespan by altering signaling through cyclic-
AMP/protein kinase A (cAMP/PKA) (Fabrizio et al., 2003), down-
regulation of which is sufficient to extend both replicative and
chronological lifespan (Fabrizio et al., 2001, 2004; Lin et al.,
2000). This role of cAMP/PKA in aging may be conserved in
mammals, as disruption of adenylyl cyclase 50 and PKA function
extend murine lifespan (Enns et al., 2009; Yan et al., 2007). How-
ever, cAMP/PKA are not generally considered mediators of Ras
function in metazoa. Instead, our data suggest that signaling
through Erk and the ETS TFs mediates the longevity response
to Ras. Interestingly, fibroblasts isolated from long-lived mutant
strains of mice and long-lived species of mammals and birds
show altered dynamics of Erk phosphorylation in response to
stress (Elbourkadi et al., 2014; Sun et al., 2009), further suggest-
ing a link between Erk activity and longevity. Importantly, the ETS
TFs are conserved mediators of Ras-Erk signaling in mammals
(Sharrocks, 2001). Investigation of the effects of Ras inhibition
on mammalian lifespan and the role of the mammalian Aop
ortholog Etv6 are now warranted.
Ras-Erk-ETS Inhibitors as Potential Anti-Aging
Therapeutics
A role for Ras-Erk-ETS signaling in lifespan offers multiple poten-
tial targets for small-molecule inhibitors that could function as
anti-aging interventions. Importantly, due to the key role of this
Figure 6. Model of Aop-Foxo Function Downstream of IIS
We propose that, downstream of the insulin receptor substrate, Chico,
signaling via the IIS pathway bifurcates into two branches: Ras-Erk and PI3K-
Akt. At the transcriptional level, these two branches subsequently re-join,
acting on the Aop and Foxo TFs in a non-additive manner. The two TFs then
co-operatively regulate the expression of a subset of target genes required for
lifespan extension.
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pathway in cancer, multiple such inhibitors exist or are in devel-
opment (Neuzillet et al., 2014).
We have shown that trametinib, a highly specific allosteric in-
hibitor of the Mek kinase (Yamaguchi et al., 2011), prolongs
Drosophila lifespan, thus validating the Ras-Erk-ETS pathway
as a pharmacological target for anti-aging therapeutics. Trame-
tinib joins a very exclusive list of FDA-approved drugs that pro-
mote longevity in animals (de Cabo et al., 2014), the most
convincing other example being rapamycin.
Rapamycin not only increases lifespan in multiple organ-
isms, including mammals, but also improves several indices
of function during aging (Ehninger et al., 2014; Lamming
et al., 2013). While rapamycin can protect against tumor
growth (Anisimov et al., 2011), the effects on longevity appear
to be independent of cancer prevention, as rapamcyin-treated
animals still develop tumors (Harrison et al., 2009) and rapa-
mycin can increase lifespan in tumor-free species (Bjedov
et al., 2010). Furthermore, increased activity of certain tumor
suppressors such as lnk4a/Arf and PTEN as well as the
RasGrf1 deficiency all increase lifespan independently of
anti-tumor activity (Borra´s et al., 2011; Matheu et al., 2009;
Ortega-Molina et al., 2012). Our findings that trametinib can in-
crease lifespan in Drosophila, which are mainly post-mitotic in
adulthood, and that doses of trametinib that increase lifespan
do not alter proliferation rates of ISCs in Drosophila suggest
that the anti-aging effects of trametinib are separable from
its anti-cancer activity.
Finally, due to the high degree of evolutionary conservation in
the Ras-Erk-ETS pathway, our study suggests the intriguing
possibility that pharmacological inhibition of Ras-Erk-ETS may
also increase lifespan in mammals.
EXPERIMENTAL PROCEDURES
Fly Stocks and Husbandry
Stocks were maintained and experiments conducted at 25C on a 12 hr:12 hr
light:dark cycle at 60% humidity, on food containing 10% (w/v) brewer’s yeast,
5% (w/v) sucrose, and 1.5% (w/v) agar unless otherwise noted. RU486 (Sigma)
dissolved in ethanol was added to a final concentration of 200 mM. Trametinib
(LC Laboratories) was added from a 62.4 mM stock solution in DMSO main-
taining a final DMSO concentration of 0.25% (v/v). For control treatments,
equivalent volumes of the vehicle alone were added. Stocks were back-
crossed for at least six generations into the wild-type outbredwDahomey pop-
ulation, with the exception of UAS-ras85D[RNAi] and UAS-rl[RNAi], which were
used as hybrids. Drosophila stocks, cloning strategies, and phenotyping are
described in the Supplemental Experimental Procedures. For lifespans, flies
were sorted into experimental vials at a density of 10 or 15 flies per vial. Flies
were transferred to fresh vials three times a week, and deaths/censors were
scored during transferral.
Bimolecular Fluorescence Complementation Assays
Constructs encoding the wild-type Chico protein or Chico Grb2/Drk-binding
site mutant and Drosophila Drk were transfected into S2 cells. After 3 days,
cells were serum starved for 2 hr and then stimulated with 1 mM human insulin
(Sigma) for 24 hr before imaging.
Immunofluorescence
Aop immunofluorescence was performed on dissected adult abdominal fat
bodies using a monoclonal mouse anti-AOP antibody (Rebay and Rubin,
1995) at 1:100 dilution. Phospho-histone H3 immunofluorescence was per-
formed on dissected adult midguts using a polyclonal rabbit phospho-histone
H3 (Ser10) antibody (Cell Signaling).
Western Blots
S2 cells were serum starved for 2 hr, treated with trametinib dissolved
in DMSO or DMSO alone for 30 min, and then stimulated with 1 mM human in-
sulin (Sigma) for 15 min. Western blots were probed for phospho-Erk(Thr202/
Tyr204) (#4370), phospho-Akt(Ser473) (#4060), phospho-S6K(Thr398) (#9209),
total-Erk (#4695), total-Akt (#9272) (Cell Signaling Technologies), total-S6K,
and tubulin.
qRT-PCR Analysis
Total RNA was isolated from either five whole adult flies or five dissected
abdominal fat bodies using standard TRIZOL (Invitrogen) protocols and con-
verted to cDNA using oligod(T) primer and Superscript II reverse transcriptase
(Invitrogen). Quantitative RT-PCR was performed using Power SYBR Green
PCR Master Mix (ABI), and relative quantities of transcripts were determined
using the relative standard curve method normalized to actin5C. See Supple-
mental Experimental Procedures for primer sequences.
Statistical Analysis
Statistical analysis was performed in Excel (Microsoft), Jmp version 9 (SAS
Insitute), or R, except for mortality analysis in which survival data were fitted
to the Gompertz model using Survomatic online. Statistical tests used are indi-
cated in the figure captions. See the Supplemental Experimental Procedures
for further details.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
six figures, and five tables and can be found with this article online at http://
dx.doi.org/10.1016/j.cell.2015.06.023.
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